In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API.
Insulin API is widely used in Fast-acting, Intermediate-acting and Long-acting Product. The most proportion of Insulin API is used in Long-acting, and the proportion in 2019 is about 41%.
The global Insulin API market was valued at US$ 1664.2 million in 2019 and is expected to reach US$ 2013.8 million by the end of 2026, growing at a CAGR of 2.9% during 2021-2026.
This report focuses on Insulin API volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Insulin API market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Insulin API Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Regular Human Insulin
Segment by Application
Middle East & Africa
Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region